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Objective. To investigate if antibodies towards biological TNF-𝛼 inhibitors (anti-TNFi Abs) are present in patients with rheumatoid
arthritis (RA) in clinical remission and to relate any anti-TNFi Abs to circulating level of TNF-𝛼 inhibitor (TNFi).Methods. Patients
with RA, treated with infliximab or adalimumab, and in clinical remission (DAS28(CRP) < 2.6) were included from 6 out-patient
clinics. In blood samples, presence of anti-TNFi Abs was determined by radioimmunoassay, and concentration of bioactive TNFi
wasmeasured by a cell-based reporter gene assay.Results. Anti-TNFi Abswere present in 8/44 patients (18%) treatedwith infliximab
and 1/49 patients (2%) treated with adalimumab (𝑝 = 0.012). In the former group, anti-TNFi Abs corresponded with low levels of
TNFi (𝑝 = 0.048). Anti-TNFi Ab-positive patients had shorter disease duration at initiation of TNFi therapy (𝑝 = 0.023) but were
similar for the rest of the compared parameters. Conclusions. In RA patients in clinical remission, anti-TNFi Abs occur frequently
in patients treated with infliximab, while they occur rarely in patients treated with adalimumab. Presence of anti-infliximab Abs is
accompanied by low or undetectable levels of infliximab.These data suggest that continued infliximab treatment may be redundant
in a proportion of RA patients treated with infliximab and in clinical remission.
1. Introduction
Biologic disease-modifying antirheumatic drugs (bio-
DMARDs), especially in the form of TNF-𝛼 inhibitors
(TNFi), are established treatment options for patients with a
wide variety of immunoinflammatory rheumatic diseases,
including rheumatoid arthritis (RA). Since the millennium,
knowledge regarding who, when, and how to treat with
TNFi has increased greatly, and the aim has moved from
suppression of symptoms towards disease control. As bio-
logic medications have potentially life threatening side effects
and are expensive, redundant treatment should be avoided.
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Some patients develop antibodies against TNFi (anti-
TNFi Abs) and most of these antibodies neutralize the
effect of the TNFi [1–5]. A relationship has been established
between circulating levels of anti-TNFi Abs and low levels of
TNFi, as well as impaired clinical response [1–3]. Although
the mechanisms underlying this immunological reaction are
largely unknown, basic pharmacoimmunological informa-
tion may be used to improve the use of TNFi therapies.
For instance, patients in clinical remission having high levels
of anti-TNFi Abs and low levels of TNFi may not benefit
from further medication, as maintained remission could be
independent of continued TNFi administration [6]. Stopping
unnecessary medication would reduce further immunization
and the associated safety issues in these individuals and it
would greatly reduce the costs of treatment. To estimate the
potential of such a strategy, we investigated the presence of
antibodies against infliximab and adalimumab, and circu-
lating levels of the corresponding TNFi, in RA patients in
clinical remission.
2. Patients and Methods
2.1. Patients. Through the nationwide DANBIO registry,
patients fulfilling the 2010 [7] or 1987 [8] consensus criteria
for RA were considered for enrollment in the study. The
patients were included from 6 different locations,minimizing
geographical selection bias. Inclusion criteria were age of 18
years or older, treatment with infliximab or adalimumab for
at least one year, and clinical remission defined as disease
activity score in 28 joints (DAS28(CRP)) less than 2.6 [9]
at the time of the inclusion. It was not a requirement that
patients had to have a shorter or longer history of remission
at time of inclusion. Previous therapy with TNFi or other
bio-DMARDs did not disqualify inclusion. The 223 patients
complying with the inclusion criteria according to DANBIO
received a letter with an invitation to study participation.
Of these, 111 patients replied positively to the invitation,
and a study appointment was made. Eight patients either
did not attend this scheduled visit or were excluded at the
visit, and following the physical examination and the new
DAS28(CRP) based on parameters obtained at the study visit,
further 10 patients had to be excluded, leaving 93 patients
included.
The study was approved by the local ethics com-
mittee of Region Zealand and all patients gave written
informed consent prior to inclusion in accordance with the
Declaration of Helsinki (http://www.wma.net/en/30publica-
tions/10policies/b3/).
2.2. Data Collection. The patients were included in the study
for one study visit only andwere not followed up by the inves-
tigators afterwards. The patents continued in their respective
out-patient clinic as they had done prior to the study. Dis-
ease activity was assessed at inclusion by DAS28(CRP) [10]
along with information on concomitant medication. From
patient files and from the DANBIO registry, information
was obtained from two time points: study inclusion and
retrospectively at TNFi initiation. The information included
age, gender, duration of disease and clinical remission, TNFi
treatment and concomitant medication, and anti-CCP Ab
and IgM rheumatoid factor (IgM-RF) status.
Clinical efficacy of TNFi treatment was evaluated retro-
spectively through DANBIO records by change in
DAS28(CRP) from TNFi initiation until registered
DAS28(CRP) at the 6-months visit or closest thereafter.
EULAR responses were defined as good, moderate or
no response (improvement in DAS28(CRP) > 1.2 and
DAS28(CRP) ≤ 3.2; improvement in DAS28(CRP) > 1.2
and DAS28(CRP) > 3.2 or improvement in DAS28(CRP)
between 0.6 and 1.2 and DAS28(CRP) ≤ 5.1; improvement
in DAS28(CRP) < 0.6 or improvement in DAS28(CRP)
between 0.6 and 1.2 and DAS28(CRP) > 5.1) [11].
Presence of anti-TNFi Abs and level of TNFi were
determined at one time point only, that is, at inclusion in the
study and when patients were in remission. Blood samples
for the study were drawn as close to the next medication with
TNFi as possible in order to assess trough levels of circulating
TNFi. In addition to analyses for TNFi and anti-TNFi Abs,
sera were analyzed for C-reactive protein (CRP) using a kit
for high sensitive CRP (Abbott Laboratories, Copenhagen,
Denmark).
2.3. Measurements of Serum Levels of TNFi (Infliximab and
Adalimumab) and Anti-TNFi Antibodies. Bioactive TNFi
levels were measured by reporter gene assays (RGA) (iLite
Infliximab Bioassay and iLite Adalimumab Bioassay, resp.,
Biomonitor, Copenhagen, Denmark) as previously described
[12, 13]. The assays for infliximab and adalimumab are based
on the human erythroleukemic K562 cell line transfected
with an NF𝜅B-regulated firefly luciferase (FL) reporter-gene
construct [12]. The cells also contain a renilla luciferase (RL)
reporter-gene under the control of a constitutive promoter
that allows TNF-𝛼-induced FL to be normalized relative to
RL expressionmaking results less dependent on cell numbers
and differences in cell viability and reducing the influence of
serum matrix effects.
TNFi levels were assessed by preparation of increasing
concentrations of infliximab or adalimumab in 100 𝜇L of
RPMI 1640 in 96-well microtiter plate.These TNFi standards
and 100 𝜇L of serially diluted (final 50-fold to 781-fold)
serum sample to be tested were preincubated with 2 ng/mL
final concentration of human recombinant TNF-𝛼 (R&D,
Minneapolis, MN, USA). After 30min at 37∘C, a human
erythroleukemic K562 cell line transfected with an NF𝜅B-
regulated firefly luciferase (FL) reporter-gene was added
to each well. After 3 hours at 37∘C, Dual-Glo Luciferase
substrate (Promega, Fitchburg, WI, USA) was added, and
the cells were then read for FL activity using a Wallac
Victor Light 1420 luminometer (Perkin-Elmer, Waltham,
MA, USA). Subsequently, Dual-Glo Stop & Glo reagent
(Promega) was added to each well, and the RL activity was
read. Normalizationwasmade by dividing the FLwith the RL
activity in each well. Calculations of the bioactive drug levels
in serum were carried out on the basis of the linear part of
the calibration curve. Sample concentrations were expressed
as drug equivalents in 𝜇g/mL.
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Table 1: Demographic characteristics of study cohort at time of




n = 49 𝑝
Age, years 63 (52–71) 54 (46–68) 0.033
Female gender, 𝑛 (%) 27 (61) 28 (57) 0.833
CRP, mg/L 2.3 (1.0–4.2) 1.6 (0.8–3.2) 0.236
DAS28(CRP) 1.6 (1.3–2.0) 1.6 (1.3–2.0) 0.939
Methotrexate use at
inclusion, (%) 39 (89) 40 (82) 0.396
Disease duration, years 11 (7–19) 16 (9–23) 0.205
Duration of biologic
therapy, months 55 (37–77) 68 (30–93) 0.328
Remission duration,
months 17 (11–26) 20 (11–42) 0.609
Continuous variables are expressed as medians (interquartile ranges).
Anti-infliximab and anti-adalimumab antibodies were
measured by fluid-phase radioimmunoassay (RIA) (Biomon-
itor) as previously described [1, 14]. Anti-TNFi Ab-positivity
was defined as detectable or undetectable levels (limit of
quantification (LOQ) 10 arbitrary units (U)/mL) of anti-
infliximab or anti-adalimumab antibodies.
2.4. Statistical Analysis. Differences between treatment
groups and anti-TNFi Ab-positive and -negative patients
were assessed by the Mann-Whitney test for continuous data
or the Fischer exact test for categorical data. Two-sided 𝑝
values less than 0.05 were considered statistically significant.
Analyses were performed using the statistical software
SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and
GraphPad Prism version 5.04 (GraphPad Software, San
Diego, CA, USA). Data are primarily reported as medians
(interquartile ranges) or percentages.
3. Results
Ninety-three RA patients were included, 44 treated with
infliximab and49 treatedwith adalimumab. For baseline vari-
ables, please see Table 1. The patients had received TNFi for a
median of 5 years (IQR 3–7 years) and had been in remission
for a median of 17 months (IQR 11–33 months). At TNFi
initiation, the median disease duration was 14 years (IQR 8–
22 years) and themeanDAS28(CRP)was 4.5 (range 1.4 to 7.5).
25/44 patients on infliximab were treated with standard dose
and frequency, 9 with a decrease in dose or frequency, and
10 with an increase in dose or frequency. For adalimumab,
34/49 patients were treated with standard regimen, 13 with
reduced frequency, and 2 with increased frequency. The vast
majority of patients were also treated withmethotrexate from
initiation of the biological treatment; 41 of 44 (93%) patients
were treated with infliximab and 41 of 49 (84%) were treated
with adalimumab. In the infliximab group, one patient started
and 3 patients stopped methotrexate between initiation of
biologic therapy and sampling for the present study. In the
adalimumab group, 5 patients started and 6 patients stopped
Table 2: Anti-TNFi Ab in rheumatoid arthritis patients in remission




𝑛 = 49 𝑝
Anti-TNFi Ab-pos, % (95% CI) 18 (7–30)(𝑛 = 8)
2 (NA)
(𝑛 = 1) 0.012
Table 3: Serum levels of TNF-𝛼 inhibitor in rheumatoid arthritis





Infliximab, 𝜇g/mL 4.7 (2.9–8.0)(𝑛 = 25)
1.6 (0.7–4.6)
(𝑛 = 6) 0.048
Adalimumab, 𝜇g/mL 9.7 (6.5–11.7)(𝑛 = 41)
0.7
(𝑛 = 1)
Continuous variables are expressed as medians (interquartile ranges).
Table 4: Initial efficacy (6–12 months) of treatment with infliximab








ΔDAS28(CRP) 2.20 (1.5–3.3) 1.4 (0.9–1.2) 0.212
EULAR good
responders, 𝑛 (%) 52 (79) 6 (67) 0.503
Continuous variables are expressed as medians (interquartile ranges);
ΔDAS28(CRP): decrease in disease activity score in 28 joints; EULAR:
European League Against Rheumatism.
methotrexate in the same period. All patients developing
anti-TNFi Abs had been treated with methotrexate from
initiation of TNFi therapy and until sampling for the present
study.
For patients treated with adalimumab, a median of 10
days (IQR 6–14 days) had passed from the last administration
of adalimumab and until blood samples for the study were
drawn. For patients treated with infliximab, a median of 46
days (IQR 34–55 days) had passed.
Anti-TNFi Abs were found in 9 of the included patients
(10%): eight of 44 patients (18% (95% CI 7–30%)) treated
with infliximab and one of 49 patients (2%) treated with
adalimumab (Table 2). The difference in frequency of anti-
TNFi Abs between the two drugs was statistically significant.
For the evaluation of TNFi concentration, data from
73 patients were available. The anti-infliximab Ab-positive
patients had significantly lower infliximab concentration
(median 1.6 𝜇g/mL) compared with the anti-infliximab Ab-
negative patients (median 4.7 𝜇g/mL) (Table 3).
Data from 75 patients (39 treated with infliximab and 36
treated with adalimumab) were available for the retrospective
evaluation of clinical efficacy of TNFi treatment (Table 4).
The change inDAS28(CRP) observed in the first 6–12months
following initiation of TNFi treatment did not differ between
the anti-TNFi Ab-positive and -negative patients. Good
EULAR response was observed in 58 patients (77%), whereas
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Table 5: Characteristics of anti-TNFi Ab-negative and -positive
rheumatoid arthritis patients in remission.
Anti-TNFi
Ab-negative
𝑛 = 84 (90%)
Anti-TNFi
Ab-positive
𝑛 = 9 (10%)
𝑝
Age, years 57 (50–69) 55 (46–66) 0.559
Female gender, 𝑛 (%) 47 (56) 8 (89) 0.077
Seropositivity, 𝑛 (%) 62 (74) 7 (78) 1.000
Duration of biologic
therapy, months 60 (35–88) 50 (38–70) 0.413
Remission duration,
months 18 (10–33) 17 (16–27) 0.537
Continuous variables are expressed as medians (interquartile ranges).
4 patients were nonresponders (5%), and the frequency of
good EULAR response did not diverge between the anti-
TNFi Ab-positive and -negative groups. Patients who later
proved anti-TNFi Ab-positive presented with either good or
moderate EULAR responses after initiation of TNFi therapy.
At inclusion in the study, the anti-TNFi Ab-positive and
-negative patients were similar in regard to age, gender, anti-
CCP or IgM rheumatoid factor-positivity, and duration of
remission (Table 5).
The anti-TNFi Ab-positive patients had significantly
shorter disease duration at TNFi initiation (Table 6).Noother
parameters investigated differed between the two groups, and
none of the anti-TNFi-Ab positive patients had been on a
prior bio-DMARD.
4. Discussion
In our cohort of RA patients in clinical remission, anti-
TNFi Abs were present in a significant percentage of patients
receiving infliximab (18%) but only rarely seen in a similar
group of adalimumab treated patients (2%). This difference
in immunogenicity in the two groups of patients may result
from the differences in drug immunogenicity, as infliximab
is composed of non-human residues while adalimumab is
not. The difference in immunogenicity may also stem from
differences in the two patient populations, although we
only found a difference in median age at time of inclusion.
The observation of patients treated with infliximab being
older than patients treated with adalimumab may reflect the
practice of prescribing an i.v. administered drug to older
patients, and a self-administered s.c. formulation to younger
patients. We cannot say if age and age-related factors may
influence immunogenicity and development of anti-TNFi
Abs.
One would expect that anti-TNFi Ab-positive patients
showed less initial improvement, since the presence of anti-
TNFi Abs is associated with impaired clinical response [1–
3]. This was not the case in our cohort. The frequency of
good EULAR response following initiation of therapy did
not diverge between the later defined anti-TNFi Ab-positive
and -negative groups. Patients who later proved anti-TNFi
Ab-positive presented with either good or moderate EULAR
responses in the first 6–12 months of treatment. A likely
explanation is that anti-TNFi Abs did not form until later
in the treatment course, at a time when the patient had
already reached TNFi independent remission, and patients
with disease relapse would not meet the inclusion criteria
of remission for the present study. Of course this is only
hypothetical, as we have no information regarding the timing
of anti-TNFi Ab development.
The frequency of anti-TNFi Abs in patients with a good
clinical response to therapy is in accordance with previous
studies. These studies report anti-TNFi Ab development in
4% to 44% of patients in remission as well as with good
EULAR response [1–4, 15].
Interestingly, recent evidence suggests that TNF-𝛼, as a
predominant mediator of chronic inflammatory processes,
may fade with time. This could be of potential importance
for patients receiving long-term TNFi therapies. For exam-
ple, some patients with inflammatory bowel disease lose
responsiveness to continued infliximab administration in the
presence of high levels of TNF-𝛼neutralizing activity induced
by the previously active drug [14]. If similar changes in
pharmacodynamics occur in a subset of patients with RA,
that is, that TNF-𝛼 ceases to contribute to inflammation after
prolonged TNFi therapy, these patientsmight be in remission
regardless of receiving sustained TNFi therapy. Indeed, TNF-
𝛼 as a pathogenic factor may have been lost in our anti-
infliximab Ab-positive patients since they are in remission
despite an assumed Ab-mediated neutralization of the drug
during infusions.
Inconsistency in the occurrence of anti-TNFi Abs
reported in the literature might be explained by the different
techniques used to detect anti-TNFi Abs. Since the discovery
of TNFi immunogenicity and anti-TNFi Ab development,
reliable detection and quantification of anti-TNFi Abs have
become important [16–18]. The most commonly used tech-
nique is based on a solid phase, bridging-type enzyme-linked
immunosorbent assay (ELISA). Unfortunately, this technique
has major limitations for clinical use, as it is unable to
detect anti-TNFi Abs in the presence of TNFi. Furthermore,
IgG4 anti-TNFi Abs, predominant in long-term immunized
patients, also escape detection [16–20]. Solid-phase tech-
nologies may also yield false positive and false negative test
results due to interference with serum factors and matrix
effects.We, therefore, used amore specific and sensitive fluid-
phase radioimmunoassay (RIA) for quantification of both
anti-infliximab and anti-adalimumab Abs [18]. The RIA for
detection of anti-TNFi Abs is the more sensitive method
when compared to several other available assays [13]. The
impact of residual TNFi on performance of the RIA assay
is not known, but it seems that very large concentration of
TNFi is needed to completely mask anti-TNFi Abs [1], and it
seems that other available assays may be more prone to false
negative results on anti-TNFi Ab formation in presence of
residual drug [20].
Using a newly developed cell-based assay [12], we found
that anti-infliximab Ab-positivity was associated with low
serum levels of functionally active drug, suggesting that
the antibodies measured by RIA were capable of removing
infliximab from the circulation and/or neutralizing drug
activity in vivo, being of therapeutic significance. It has
Arthritis 5
Table 6: Patient characteristics at initiation of TNF-𝛼 inhibitor therapy and at study inclusion.





Negative Positive Negative Positive
Disease duration, years 10 (4–18) 2 (2–10) 0.027 15 (8–23) 8 (5–16) 0.045
Methotrexate, 𝑛 (%) 73 (87) 9 (100) 0.250 69 (82) 9 (100) 0.346
Methotrexate, mg/week 15 (7.5–20) 20 (20–22.5) 0.070 10 (7.5–15) 15 (7.5–15) 0.389
Glucocorticoid, 𝑛 (%) 18 (21) 2 (22) 0.979 4 (5) 0 0.506
Glucocorticoid, mg/day 0 (0) 0 (0) 0.822 0 (0) 0 0.993
Continuous variables are expressed as medians (interquartile ranges).
previously been shown that anti-TNFi Abs bind to the TNF-
𝛼 binding site [5]. The association between anti-infliximab
Ab development and low serum levels of infliximab is in
accordance with other studies [2, 15, 21]. The single anti-
adalimumab Ab-positive patient also exhibited a very low
level of adalimumab. Associations between anti-adalimumab
Abs, low circulating drug levels, and loss of response have
been established in other studies of RA patients [2, 3, 22].
Several previous studies have found an association
between the use of concomitant methotrexate and a dimin-
ished occurrence of anti-TNFi Abs [3, 23, 24], but other
investigators have not found this association [15, 25]. In our
study we did not find any association between the use of
methotrexate and anti-TNFi Ab development. This could be
ascribed to the limited number of anti-TNFi Ab-positive
individuals. Alternatively, methotrexate may influence anti-
TNFi Ab levels not by its immunosuppressive effect but by
its anti-inflammatory effect [17]. This is supported by the
fact that all of our patients were in clinical remission. In this
case, methotrexate may suppress inflammation (as intended)
and thereby aid the TNFi in exerting its effect. Anti-TNFi
Abs may be more prone to development if inflammation
is insufficiently suppressed. If this is the case, an effect
of methotrexate on anti-TNFi Ab levels is only seen in
patients with active inflammation, not in patients in long-
term remission (the present study). This is supported by the
fact that development of anti-TNFi Abs has been associated
with lower serum levels of infliximab early in the course of
therapy, higher baseline CRP, and higher baseline DAS [1–
3, 21].
Contrary to our findings, previous studies have reported
longer disease durations in anti-TNFi Ab-positive patients
when compared to anti-TNFi Ab-negative patients [3, 26].
The mean disease durations in these studies were approx-
imately eight years, whereas the mean disease duration in
our study was 16 years. It must be noted, however, that
our cohort selectively consisted of patients in remission,
whereas previous studies included patients with ongoing
active disease. This difference in patient composition might
also explain that the proportion of our patients achieving
good EULAR responses is greater than what is generally
reported, that is, about one-third [2, 22, 27, 28]. A further
explanation for the anti-TNFi Ab-positive patients having
shorter disease duration at the initiation of therapy may be
that the patients with more active (inflammatory) disease are
more likely to be treated with TNFi early in their course of
disease. And as previously mentioned anti-TNFi Abs have
been associated with higher baseline DAS and CRP.
5. Conclusion
To our knowledge, this is the first study to measure anti-
TNFi Abs in a cohort of RA patients solely in remission.
Despite a median period of remission of 17 months, the
patients were still on TNF-𝛼 inhibitor treatment. We found
that 18% (95% CI 7–30%) of infliximab-treated patients
in remission had detectable levels of anti-infliximab Abs,
and this corresponded to low or absent levels of bioactive
infliximab in the blood circulation.We know there is an asso-
ciation between anti-infliximab Abs, low circulating levels
of infliximab, and (later) therapeutic failure, and we suspect
that TNF-𝛼-dependency of chronic inflammation may fade
with time in some patients. Hence, we hypothesize that
patients achieving remission despite having low drug levels
and anti-infliximab Abs may be in remission independent
of the use of infliximab. Continued therapy may, therefore,
be redundant in these cases. Due to safety issues associated
with continuous drug-induced immunization, as well as
economic considerations, we suggest further investigations of
whether infliximab treatmentmay be tapered or discontinued
in patients with low drug levels and accompanying anti-
TNFi Abs. Due to safety issues associated with continuous
drug-induced immunization, as well as economic considera-
tions, we suggest further investigations of whether infliximab
treatment may be tapered or discontinued in patients with
low drug levels and accompanying anti-TNFi Abs, without
compromising clinical remission.
According to our data, the issue of antibody formation
in RA patients in clinical remission is mainly relevant to
infliximab, but it might also be considered in case of long-
term remission in patients treated with adalimumab. Future
studies may confirm if measurements of anti-TNFi Abs and
drug levels will aid in determiningwhen to taper or stopTNFi
treatment in RA patients in remission.
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